Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

ONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Astrazeneca Ab🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 18, 2024
Approval ID: afab21d00097de01
Company: Astrazeneca Ab
Type: Standard

Approval Details

Approval Id: afab21d00097de01
Drug Cima Aemps Name: ONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 09545006IP
Holder Company Name: Astrazeneca Ab
Marketing Company Name: Elam Pharma Labs S.L.
Holder Company Detail Path: /organization/astrazeneca-ab
Authorization Date: 2024-07-18
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Astrazeneca Ab
Company Detail Path: /organization/astrazeneca-ab

Company Information

Pharmaceutical Company Name: ASTRAZENECA AB
Country Name: Spain
City Name: madrid,madrid,country_es
Address: CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Website: http://www.astrazeneca.se

Active Ingredients

SAXAGLIPTINA HIDROCLORURO

5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 18, 2024

Approval ID

afab21d00097de01

Type

Standard

Back to CIMA-AEMPS Approvals